Overview

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Status:
Not yet recruiting
Trial end date:
2030-12-25
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline